# ClinicalTrials.gov record NCT01237119

> PeptideScanner retained ClinicalTrials.gov record NCT01237119 at 2026-07-30T21:38:42.856Z. Its registry update date was 2016-03-23, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01237119-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-03-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01237119-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct01237119-liraglutide-v1.json
- Content SHA-256: `36f0ed9ba19f025db6c5bf8f13304b0642ec800426ebe649c604dec7402168dd`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT01237119 ([`ctg-observation-nct01237119-2016-03-23-9fc751a5d438`](#source-ctg-observation-nct01237119-2016-03-23-9fc751a5d438))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01237119 at 2026-07-30T21:38:42.856Z. Its registry update date was 2016-03-23, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01237119-2016-03-23-9fc751a5d438`](#source-ctg-observation-nct01237119-2016-03-23-9fc751a5d438))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01237119 at 2026-07-30T21:38:42.856Z. Its registry update date was 2016-03-23, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01237119-2016-03-23-9fc751a5d438`](#source-ctg-observation-nct01237119-2016-03-23-9fc751a5d438))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01237119-2016-03-23-9fc751a5d438`](#source-ctg-observation-nct01237119-2016-03-23-9fc751a5d438))

## Sources

<a id="source-ctg-observation-nct01237119-2016-03-23-9fc751a5d438"></a>
- **ClinicalTrials.gov record NCT01237119 · retained source version 2016-03-23:9fc751a5d438338bbd956465199469975b22c82ed8b16150659175b3a0748cab** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01237119) (`ctg-observation-nct01237119-2016-03-23-9fc751a5d438`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01237119." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct01237119-liraglutide-v1.json SHA-256: 36f0ed9ba19f025db6c5bf8f13304b0642ec800426ebe649c604dec7402168dd.